



April 16, 2025

**VIA EDGAR**

United States Securities  
and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Margaret Sawicki

**Re: bioAffinity Technologies, Inc.  
Registration Statement on Form S-1  
Filed April 11, 2025  
File No: 333-286497**

---

Dear Ms. Sawicki:

bioAffinity Technologies, Inc. (the “**Registrant**”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-286497), be accelerated by the U.S. Securities and Exchange Commission (the “**Commission**”) to become effective on **Friday, April 16, 2025**, at **5:00 p.m.**, Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Leslie Marlow at (212) 885-5358 or Melissa Palat Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Very truly yours,

BIOAFFINITY TECHNOLOGIES, INC.

By: /s/ Maria Zannes  
Name: Maria Zannes  
Title: Chief Executive Officer

cc: Leslie Marlow, Blank Rome LLP  
Melissa Palat Murawsky, Blank Rome LLP

---